FIG 5.
Induction of CNS αS inclusion pathology in M83+/− mice following i.m. injection of αS fibs and soluble αS. (A and B) Representative images showing αS inclusion pathology in the brain stem (A) and spinal cord (B) of M83+/− mice i.m. injected with 20 μg mouse αS fibs. (C and D) Representative images showing αS inclusion pathology in the brain stem (C) and spinal cord (D) of an M83+/− mouse that was i.m. injected with 20 μg soluble human αS that developed motor impairments. (E) Representative images showing αS inclusion pathology in the brain stem of one of the M83+/− mice i.m. injected with 20 μg Δ71-82 αS that developed motor impairments. Paucity of αS inclusion pathology as shown in the brain stems of M83+/− mice i.m. injected with 20 μg βS (F) or KLH (G). Tissue sections were stained with antibodies to αS phosphorylated at Ser129 (EP1536Y and 81A), anti-αS (Syn 506), or anti-p62/sequestosome (a general marker of inclusion pathology) as indicated in each panel. Tissue sections were counterstained with hematoxylin. Bars = 100 μm.